Abstract
Estrogen stimulates maternal behavior in rats, but does so most potently when its administration is temporally coupled with the termination of pregnancy. In contrast, this effect of estrogen is blocked when subjects are administered a large dose of progesterone concurrent with estrogen. The current study was performed to examine the neural circuitry influenced by these treatments and pup presentation during the hormonally-mediated onset and inhibition of maternal behavior. In experiment I, estrogen induced c-Fos immunoreactivity (Fos-IR) in the medial preoptic area (MPOA) in virgin rats, but was much more effective when administered to pregnancy-terminated rats, suggesting that pregnancy termination increases MPOA’s susceptibility to the physiological effects of estrogen. In experiment II, administering progesterone concurrently with estrogen in pregnancy-terminated rats strongly inhibited estrogen-stimulated Fos-IR in the MPOA, indicating that the physiological effects of estrogen on the MPOA are blocked if high progesterone levels are maintained. In experiment III, pregnancy-terminated subjects were administered estrogen, progesterone, or both hormones and presented with pups for 2 h. Approximately half of the subjects administered estrogen alone showed maternal behavior, but subjects receiving the other treatments were not maternal. In the MPOA, ventral bed nucleus of the stria terminalis (BSTv), and dorsal and intermediate lateral septum (LSd,i), maternal subjects showed the highest levels of Fos-IR, whereas subjects treated with progesterone alone or progesterone in combination with estrogen showed low levels of Fos-IR. These experiments suggest that estrogen could promote maternal behavior by enhancing pup-stimulated activity in the MPOA, BSTv, and LSd,i, regions believed to constitute the neural circuit that promotes maternal behavior, whereas progesterone could inhibit maternal behavior by inhibiting neural activity in some of these regions.
References
1.
Numan M: Maternal behavior; in Knobil E, Neill JD (eds): The Physiology of Reproduction, ed 2. New York, Raven Press, 1994, vol 2, pp 221–302.
2.
Bridges RS: A quantitative analysis of the roles of dosage, sequence, and duration of estradiol and progesterone exposure in the regulation of maternal behavior in the rat. Endocrinology 1984;114:930–940.
3.
Bridges RS, Robertson MC, Shiu RPC, Friesen HG, Stuer AM, Mann PE: Endocrine communication between conceptus and mother: A role for placental lactogens in the induction of maternal behavior. Neuroendocrinology 1996;64:57–64.
4.
Bridges RS, Ronsheim PM: Prolactin (PRL) regulation of maternal behavior in rats: Bromocriptine treatment delays and PRL promotes the rapid onset of behavior. Endocrinology 1990;126:837–848.
5.
Bridges RS, Rosenblatt JS, Feder HH: Serum progesterone concentrations and maternal behavior in rats after pregnancy termination: Behavioral stimulation after progesterone withdrawal and inhibition by progesterone maintenance. Endocrinology 1978;102:258–267.
6.
Doerr HK, Siegel HI, Rosenblatt JS: Effects of progesterone withdrawal and estrogen on maternal behavior in nulliparous rats. Behav Neural Biol 1981;32:35–44.
7.
Moltz H, Lubin M, Leon M, Numan M: Hormonal induction of maternal behavior in the ovariectomized nulliparous rat. Physiol Behav 1970;5:1373–1377.
8.
Numan M: Progesterone inhibition of maternal behavior in the rat. Hormones and Behavior 1978;11:209–231.
9.
Rosenblatt JS, Olufowobi A, Siegel HI: Effects of pregnancy hormones on maternal responsiveness, responsiveness to estrogen stimulation of maternal behavior, and the lordosis response to estrogen stimulation. Horm Behav 1998;33:104–114.
10.
Siegel HI, Rosenblatt JS: Hormonal basis of hysterectomy-induced maternal behavior during pregnancy in the rat. Horm Behav 1975;6:211–222.
11.
Siegel HI, Rosenblatt JS: Duration of estrogen stimulation and progesterone inhibition of maternal behavior in pregnancy-terminated rats. Horm Behav 1978;11:12–19.
12.
Jacobson CD, Terkel J, Gorski RA, Sawyer CH: Effects of small medial preoptic area lesions on maternal behavior: Retrieving and nest building in the rat. Brain Res 1980;194:471–478.
13.
Siegel HI, Rosenblatt JS: Estrogen-induced maternal behavior in hysterectomized-ovariectomized virgin rats. Physiol Behav 1975;14:465–471.
14.
Numan M, Roach JK, del Cerro MCR, Guillamón A, Segovia S, Sheehan TP, Numan MJ: Expression of intracellular progesterone receptors in rat brain during different reproductive states, and involvement in maternal behavior. Brain Res 1999;830:358–371.
15.
Kalinichev M, Rosenblatt JS, Morrell JI: The medial preoptic area, necessary for adult maternal behavior in rats, is only partially established as a component of the neural circuit that supports maternal behavior in juvenile rats. Behav Neurosci, 2000;114:196–210.
16.
Numan M: Medial preoptic area and maternal behavior in the female rat. J Comp Physiol Psychol 1974;87:746–759.
17.
Numan M, Corodimas KP, Numan MJ, Factor EM, Piers WD: Axon-sparing lesions of the preoptic region and substantia innominata disrupt maternal behavior in rats. Behav Neurosci 1988;102:381–396.
18.
Numan M, Rosenblatt JS, Komisaruk BR: Medial preoptic area and onset of maternal behavior in the rat. J Comp Physiol Psychol 1977;91:146–164.
19.
Numan M, Numan MJ: A lesion and neuroanatomical tract-tracing analysis of the role of the bed nucleus of the stria terminalis in retrieval behavior and other aspects of maternal responsiveness in the rat. Dev Psychobiol 1996;29:23–51.
20.
Fleischer S, Slotnick BM: Disruption of maternal behavior in rats with lesions of the septal area. Physiol Behav 1978;21:189–200.
21.
Sheehan TP, Numan M: The septal area and social behavior; in Numan R (ed): The Behavioral Neuroscience of the Septal Region. New York, Springer, 2000.
22.
Sheehan TP, Cirrito J, Numan MJ, Numan M: Using c-Fos immunocytochemistry to identify forebrain regions that may inhibit maternal behavior in rats. Behav Neurosci 2000;114:337–352.
23.
Fleming AS, Korsmit M: Plasticity in the maternal circuit: Effects of maternal experience on Fos-Lir in hypothalamic, limbic, and cortical structures in the postpartum rat. Behav Neurosci 1996;110:567–582.
24.
Lonstein JS, Simmons DA, Swann JM, Stern JM: Forebrain expression of c-fos due to active maternal behavior in lactating rats. Neuroscience 1998;82:267–281.
25.
Numan M, Numan MJ: Expression of Fos-like immunoreactivity in the preoptic area of maternally behaving virgin and postpartum rats. Behav Neurosci 1994;108:379–394.
26.
Numan M, Numan MJ: Importance of pup-related sensory inputs and maternal performance for the expression of Fos-like immunoreactivity in the preoptic area and ventral bed nucleus of the stria terminalis of postpartum rats. Behav Neurosci 1995;109:135–149.
27.
Numan M, Numan MJ: Projection sites of medial preoptic area and ventral bed nucleus of the stria terminalis neurons that express Fos during maternal behavior in female rats. J Neuroendocrinol 1997;9:369–384.
28.
Numan M, Numan MJ, Marzella SR, Palumbo A: Expression of c-fos, fos B, and egr-1 in the medial preoptic area and bed nucleus of the stria terminalis during maternal behavior in rats. Brain Res 1998;792:348–352.
29.
Stack EC, Numan M: Temporal course of expression of c-Fos and Fos B within the medial preoptic area and other brain regions of postpartum female rats during prolonged mother-young interactions. Behav Neurosci 2000;114:609–622.
30.
Bridges RS, Numan M, Ronsheim PM, Mann PE, Lupini CE: Central prolactin infusions stimulate maternal behavior in steroid-treated, nulliparous female rats. Proc Natl Acad Sci USA 1990;87:8003–8007.
31.
Bridges RS, Robertson MC, Shiu PC, Sturgis JD, Henriquez BM, Mann PE: Central lactogenic regulation of maternal behavior in rats: Steroid dependence, hormone specificity, and behavioral potencies of rat prolactin and rat placental lactogen I. Endocrinology 1997;138:756–763.
32.
Siegel HI, Rosenblatt JS: Progesterone inhibition of estrogen-induced maternal behavior in hysterectomized-ovariectomized virgin rats. Horm Behav 1975;6:223–230.
33.
Swanson LW: Brain Maps: Structure of the Rat Brain. Amsterdam, Elsevier, 1992.
34.
Auger AP, Blaustein JD: Progesterone enhances an estradiol-induced increase in Fos immunoreactivity in localized regions of female rat forebrain. J Neurosci 1995;15:2272–2279.
35.
Auger AP, Blaustein JD: Progesterone treatment increases Fos-immunoreactivity within some progestin receptor-containing neurons in localized regions of female rat forebrain. Brain Res 1997;746:164–170.
36.
Insel TR: Regional induction of c-fos-like protein in rat brain after estradiol administration. Endocrinology 1990;126:1849–1853.
37.
Kirkland JL, Murthy L, Stancel GM: Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology 1992;130:3223–3230.
38.
Schuchard M, Landers JP, Sandhu NP, Spelsberg TC: Steroid hormone regulation of nuclear proto-oncogenes. Endocr Rev 1993;14:659–669.
39.
Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM: Rapid membrane effects of steroids in neuroblastoma cells: Effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription. Endocrinology 1997;9:4030–4033.
40.
Wagner CK, Morrell JI: Levels of estrogen receptor immunoreactivity are altered in behaviorally-relevant brain regions in female rats during pregnancy. Mol Brain Res 1996;42:328–336.
41.
Giordano AL, Siegel HI, Rosenblatt JS: Nuclear estrogen receptor binding in microdissected brain regions of female rats during pregnancy: Implications for maternal and sexual behavior. Physiol Behav 1991;50:1263–1267.
42.
Giordano AL, Siegel HI, Rosenblatt JS: Nuclear estrogen receptor binding in the preoptic area and hypothalamus of pregnancy-terminated rats: Correlation with the onset of maternal behavior. Neuroendocrinology 1989;50:248–258.
43.
Bakowska JC, Morrell JI: Atlas of the neurons that express mRNA for the long form of the prolactin receptor in the forebrain of the female rat. J Comp Neurol 1997;386:161–177.
44.
Horseman ND, Yu-Lee L: Transcriptional regulation by the helix bundle peptide hormones: Growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 1994;15:627–649.
45.
Leaman DW, Leung S, Li X, Stark GR: Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J 1996;10:1578–1588.
46.
Bridges R, Rigero B, Byrnes E, Yang L, Walker A: Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. Endocrinology 2001;142:730–739.
47.
Le W, Attardi B, Berghorn KA, Blaustein J, Hoffman GE: Progesterone blockade of a luteinizing hormone surge blocks luteinizing hormone-releasing hormone Fos activation and activation of its preoptic area afferents. Brain Res 1997;778:272–280.
48.
Lonstein JS, Gréco B, DeVries GJ, Stern JM, Blaustein JD: Maternal behavior stimulates c-fos activity within estrogen receptor alpha-containing neurons in lactating rats. Neuroendocrinology 2000;72:91–101.
49.
Simerly RB, Swanson LW: Projections of the medial preoptic nucleus: A Phaseolus vulgaris leucoagglutinin anterograde tract-tracing study in the rat. J Comp Neurol 1988;270:209–242.
50.
Frye CA: The role of neurosteroids and nongenomic effects of progestins in the ventral tegmental area in mediating sexual receptivity of rodents. Horm Behav 2001;40:226–233.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
